SFM
ADAP

Signet Financial Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Signet Financial Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-550
Closed -$7K – 961
2018
Q2 		$7K Buy
+550
New +$6.86K ﹤0.01% 661

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Signet Financial Management's ADAP Position: Q3 2018 in Review

Signet Financial Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2018, closing a stake of 550 shares — an estimated $7K sold.

Signet Financial Management first reported a position in ADAP in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 93 funds tracked by Wall St. Rank hold ADAP as of Q3 2018.

  • Signet Financial Management reported no remaining Adaptimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Signet Financial Management sold 550 Adaptimmune Therapeutics shares in Q3 2018, an estimated $7K.
  • Signet Financial Management first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 1 quarter.
  • Signet Financial Management's Adaptimmune Therapeutics position peaked at $7K in Q2 2018.
  • 93 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2018.

Based on Signet Financial Management's 13F filing for Q3 2018, filed 14 Nov 2018.